Articles online! FADS and semi-rational design modified T7 RNA polymerase reduced dsRNA production

Breaking News! Molefuture's ZymeEditor platform has successfully reduced the dsRNA byproduct content of T7 RNA polymerase to just 1.8% of the wild-type through semi-rational design and fluorescence-activated droplet sorting techniques, relevant scientific paper is now fully available online!

This study delivers a robust methodology for identifying mutants with reduced dsRNA content and successfully isolates multiple dsRNA mutants that have reduced RNA-dependent RNA polymerase and terminal transferase activity. It substantially bolsters the validation of safety and efficacy integral to mRNA therapeutics, underscoring its profound implications for advancing mRNA vaccines and gene therapy applications.

At the same time, the parent company Yeasen has also launched a T7 RNAP product (戳链接，了解详情 ) that significantly reduces dsRNA content. If you need to apply for trial packaging or require tailor-made enzyme modification services, please feel free to contact us.

For more information, please visit the following link to view the literature: https://doi.org/10.1101/2024.05.23.595468.